Phase IV

Defence Materials Technology Centre

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19

Lead Product(s): Chloroquine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Certara

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.

Royal Melbourne Hospital

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Australian Researchers Launch ASCOT Study for Covid-19

Lead Product(s): Hydroxychloroquine Sulphate

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

The AustralaSian COVID-19 Trial is attempting to see if already established treatments might prove effective against COVID-19 which as a ‘new disease’ has no current treatments.

Faron Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FINLAND Finland

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to study the effect of interferon beta-1a in COVID-19

Lead Product(s): Interferon Beta-1A

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia program that includes intravenous interferon beta-1a as a new treatment arm has been approved.

King's College London

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

New study identifies drugs that are safe to use in COVID-19 treatment

Lead Product(s): Ibuprofen

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

Study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

Lead Product(s): Danoprevir,Ritonavir,Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

The data from this small-sample clinical study showed that danoprevir combined with ritonavir is safe and well tolerated in all patients.

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy

Lead Product(s): Danoprevir,Ritonavir,Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

All 11 patients receiving oral Ganovo and Ritonavir combination therapy have been discharged as they satisfy the discharge standards under the "Diagnosis and Treatment Program for Novel Coronavirus.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Defence Materials Technology Centre

Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19

Royal Melbourne Hospital

Australian Researchers Launch ASCOT Study for Covid-19

Faron Pharmaceuticals

Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to study the effect of interferon beta-1a in COVID-19

King's College London

New study identifies drugs that are safe to use in COVID-19 treatment

Ascletis Pharma

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

Ascletis Pharma

Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy